Cancer vaccines in development rely on mRNA technology under attack by RFK Jr. “I am concerned that this could bleed over," ...

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step ...

BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...

BioNTech SE BNTX -0.15% Get Free Report reported a narrower loss for the second quarter on Monday. The company posted a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, versus a loss of ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...

BioNTech is back in Wall Street’s spotlight after posting better-than-expected second-quarter results and doubling down on ...

BioNTech SE BNTX +3.21% Get Free Report reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus ...

The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of ...

BioNTech’s second-quarter earnings came in at a loss of 1.60 euros a share on revenue of €261 million ($302.1 million), ...

MAINZ, Germany, July 21, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2025 on Monday, August ...

BioNTech SE agreed to buy former Covid vaccine rival CureVac NV for about $1.25 billion in an all-stock transaction that will boost its growing oncology business.